Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Daunorubicin and Cytarabine in Untreated AML (Age 60-75)
NCT00742625Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Primary endpoints: Remission Induction Response Rate at 2 months and Dose-limiting Toxicity at 42 days. Started Sep 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00742625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00742625.